First pre-AI pandemic vaccine approved in EU
GlaxoSmithKline (GKS) announces that the European
Commission has granted marketing authorisation for its H5N1 adjuvanted
pre-pandemic vaccine, Prepandrixâ„¢, in all 27 EU member states.
This is the first company to obtain a European licence for a pre-pandemic
â€œThis vaccine marks a significant step in the world's ability to cope with
an influenza pandemic. It is testament to GSK scientists who have pioneered the
approach to pre-pandemic vaccination, demonstrating our commitment to doing
everything we can to help prevent the devastating effects of a pandemic and play
our part in averting this potential public health crisis,â€ said GlaxoSmithKline
CEO Jean-Pierre Garnier.
A pre-pandemic vaccine, such as Prepandrix, is produced in advance of a
pandemic. Such a vaccine is based on the currently circulating H5N1 avian
influenza virus. This vaccine would therefore play a critical role in pandemic
â€œPre-pandemic vaccination is an important strategy for addressing the
current threat of a pandemic posed by H5N1,â€ said President and General Manager
GSK Biologicals, Jean Stéphenne. â€œGSK welcomes the EU approval for Prepandrix
and remains committed to actively work with governments on their pandemic
preparedness plans to help protect against the potentially devastating impact of
This vaccine is formulated with a novel proprietary adjuvant system, which
is designed to achieve a high immune response at a low dose of antigen which is
long-lasting and active against a broad range of H5N1 strains.
Reuters has reported that GSK has received orders for Prepandrix from
several governments, including the US, Switzerland and Finland. Additionally, it
was reported that in 2007, the company sold 146 mln pounds of its pre-pandemic
vaccine and bulk antigen.
Related link:GlaxoSmithKline (GKS)
To comment, login here
Or register to be able to comment.